
Strides Shasun to acquire 3 brands from Moberg Pharma for USD 10 Million

Creates a new Global OTC division

Bangalore, March 7, 2016. Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Inc. has entered into an agreement with Moberg Pharma, Sweden and its affiliates to acquire **Jointflex, Fergon and Vanquish** brands for a total consideration of \$10 million plus inventory value at closing.

Strategic rationale

- Recent acquisitions has enabled Strides Shasun build an emerging OTC franchise both in its regulated and emerging markets. The announced acquisition strengthens Strides Shasun's strategy to build a global OTC franchise.
- The OTC portfolio now includes market leading Chemists Own umbrella brand in Australia and Nuprin in the US, acquired by erstwhile Shasun from Scolr Pharma, US. Nuprin has the global rights to the first Ibuprofen 12 hour Extended-Release (ER) tablets, as well as the associated Controlled Delivery Technology (CDT®)
- The company has also filed ANDA's that will further enhance the OTC portfolio in the US
- The Moberg brands that are currently marketed in USA, Australia and Middle East will further strengthen the OTC business.
- The OTC business has now reached a critical size and is showing promise to become an important part of the overall growth strategy

Transaction Details

- The transaction adds USD 6.1 Million of Revenues and delivers above company EBITDA margins.
- The transaction is immediately accretive and is expected to close within next four weeks.

About Strides Shasun Limited

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 12 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 6 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries.

Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides Shasun</u></p> <p>Badree Komandur, Group CFO +91 80 6784 0747</p> <p>Vikesh Kumar +91 80 6784 0827 Kannan N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------